BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6644332)

  • 21. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer cell function and modulation by alpha IFN and IL2 in AIDS patients and prodromal subjects.
    Lew F; Tsang P; Solomon S; Selikoff IJ; Bekesi JG
    J Clin Lab Immunol; 1984 Jul; 14(3):115-21. PubMed ID: 6237206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of treatment with recombinant interferon alfa on natural killer activity in patients with chronic type B lymphatic leukemia].
    Villamor N; Montserrat E; Urbano-Ispízua A; Ribera JM; Rovira M; Vives Corrons JL; Rozman C
    Sangre (Barc); 1989 Dec; 34(6):485-8. PubMed ID: 2629126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
    Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
    Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
    Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
    Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
    Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy.
    Pongnikorn S; Fongmoon D; Kasinrerk W; Limtrakul PN
    J Med Assoc Thai; 2003 Jan; 86(1):61-8. PubMed ID: 12678140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines.
    Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG
    Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes.
    Verhagen A; Mackay IR; Rowley M; Tymms M
    Nat Immun Cell Growth Regul; 1990; 9(5):325-33. PubMed ID: 2077397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural killer cytotoxic factor induction by K562 cells in patients with advanced cancer: correlation with production of interferon.
    Steinhauer EH; Doyle AT; Reed J; Kadish AS
    J Natl Cancer Inst; 1985 Dec; 75(6):1017-23. PubMed ID: 2415742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cells and interferon responses in patients with systemic lupus erythematosus.
    Tsokos GC; Rook AH; Djeu JY; Balow JE
    Clin Exp Immunol; 1982 Nov; 50(2):239-45. PubMed ID: 6817954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoreactivity of lymphocytes from draining lymph nodes, peripheral blood and tumor infiltrates from oral cancer patients.
    Mukhopadhyaya R; Tatake RJ; Krishnan N; Rao RS; Fakih AR; Naik SL; Gangal SG
    J Clin Lab Immunol; 1989 Sep; 30(1):21-5. PubMed ID: 2641790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
    Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
    Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.